BioXcel Therapeutics EBITDA | BTAI

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA BioXcel Therapeutics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-50.2 M	-66.9 M	-171 M	-159 M	-107 M	-82.1 M	-33.4 M	-19.9 M	-4.54 M	-2.12 M	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
-2.12 M	-171 M	-69.7 M

Quarterly EBITDA BioXcel Therapeutics

2026-Q2	2026-Q1	2025-Q4	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-15.8 M	-10.2 M	-	-14.2 M	-15.8 M	-10 M	-	-15.2 M	-17.2 M	-24.1 M	-	-48.2 M	-52.3 M	-	-	-38.9 M	-36.2 M	-31.4 M	-	-26.7 M	-27.5 M	-26.3 M	-	-24.7 M	-21.4 M	-14.9 M	-	-8.92 M	-8.51 M	-7.38 M	-	-5.11 M	-3.24 M	-4.29 M	-	-916 K	-565 K	-528 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-528 K	-52.3 M	-18.2 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
Фармсинтез LIFE	-22.6 M	-	-	-	Russia
AbbVie ABBV	15.8 B	$ 257.12	0.86 %	$ 455 B	USA
AbCellera Biologics ABCL	-199 M	$ 10.89	4.11 %	$ 3.25 B	Canada
Ayala Pharmaceuticals AYLA	-37.3 M	-	-	$ 7.46 M	Israel
Amryt Pharma plc AMYT	-38.6 M	-	-	$ 621 M	Britain
Evelo Biosciences EVLO	-106 M	-	-14.46 %	$ 27.9 M	USA
ASLAN Pharmaceuticals Limited ASLN	-43.7 M	-	-14.27 %	$ 1.7 M	Singapore
Acorda Therapeutics ACOR	-233 M	-	-24.86 %	$ 820 K	USA
Adaptimmune Therapeutics plc ADAP	-57.9 M	-	-15.15 %	$ 60.3 M	Britain
Advaxis ADXS	-35.9 M	-	-9.65 %	$ 45.9 M	USA
Abeona Therapeutics ABEO	-86.9 M	$ 5.42	0.18 %	$ 287 M	USA
iTeos Therapeutics ITOS	-158 M	-	-	$ 411 M	USA
Galmed Pharmaceuticals Ltd. GLMD	83 K	$ 4.63	21.05 %	$ 20 M	Israel
Akouos AKUS	-84.3 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	-123 M	-	-0.23 %	$ 916 M	USA
Allakos ALLK	-115 M	-	-	$ 28.6 M	USA
Cyclerion Therapeutics CYCN	-3.21 M	$ 23.52	458.67 %	$ 98.9 M	USA
Lexicon Pharmaceuticals LXRX	-48.3 M	$ 2.0	0.3 %	$ 726 M	USA
Allena Pharmaceuticals ALNA	-9.76 M	-	3.16 %	$ 1.9 M	USA
Alpine Immune Sciences ALPN	-43.7 M	-	-	$ 2.17 B	USA
Arbutus Biopharma Corporation ABUS	-37.8 M	$ 5.12	0.1 %	$ 981 M	Canada
Ampio Pharmaceuticals AMPE	122 K	-	-11.43 %	$ 502 K	USA
NextCure NXTC	-55.4 M	$ 7.0	0.55 %	$ 19.9 M	USA
Aridis Pharmaceuticals ARDS	-29.5 M	-	17.91 %	$ 11.1 M	USA
Nanobiotix S.A. NBTX	-10.8 M	$ 37.01	0.27 %	$ 1.77 T	France
ACADIA Pharmaceuticals ACAD	106 M	$ 27.83	0.32 %	$ 4.69 B	USA
Axcella Health AXLA	-76.6 M	-	-16.42 %	$ 249 M	USA
SQZ Biotechnologies Company SQZ	-79.2 M	-	57.95 %	$ 12.8 M	USA
Atreca BCEL	5.46 M	-	-11.76 %	$ 5.79 M	USA
Berkeley Lights BLI	-89 M	-	-7.31 %	$ 87 M	USA
Bellerophon Therapeutics BLPH	-22.4 M	-	-74.18 %	$ 955 K	USA
Achieve Life Sciences ACHV	228 K	$ 7.06	0.41 %	$ 308 M	USA
Baudax Bio BXRX	-17.9 M	-	0.59 %	$ 63 K	USA
Calithera Biosciences CALA	-41.8 M	-	-10.95 %	$ 876 K	USA
CymaBay Therapeutics CBAY	-101 M	-	-	$ 3.45 B	USA
Codiak BioSciences CDAK	-64.2 M	-	-55.98 %	$ 2.15 M	USA
ChemoCentryx CCXI	-127 M	-	-	$ 3.74 B	USA
Avid Bioservices CDMO	-7.57 M	-	-	$ 789 M	USA
AC Immune SA ACIU	-69.3 M	$ 2.76	2.6 %	$ 278 M	Schweiz
Cerevel Therapeutics Holdings CERE	-442 M	-	-	$ 7.29 B	USA
Aclaris Therapeutics ACRS	-75.9 M	$ 5.32	1.27 %	$ 652 M	USA
Checkpoint Therapeutics CKPT	-56.2 M	-	-	$ 169 M	USA
Adagene ADAG	-21 M	$ 3.4	2.72 %	$ 201 M	China
ADC Therapeutics SA ADCT	-121 M	$ 1.07	0.45 %	$ 136 M	Schweiz
Adial Pharmaceuticals ADIL	-7.8 M	$ 4.9	0.08 %	$ 3.28 M	USA
ADMA Biologics ADMA	199 M	$ 9.23	0.16 %	$ 2.2 B	USA
Adaptive Biotechnologies Corporation ADPT	-41.1 M	$ 24.2	0.08 %	$ 3.67 B	USA
Agenus AGEN	-10.2 M	$ 6.94	0.73 %	$ 206 M	USA
Agios Pharmaceuticals AGIO	-467 M	$ 33.6	0.16 %	$ 1.95 B	USA